This is the authors' abstract. We don't add key points for this paper.
Bevacizumab intrapleural infusion had higher efficiency and higher safety than intravenous infusion in the management of malignant pleural effusion caused by NSCLC. The decreased level of serum VEGF at 72 hours after bevacizumab treatment was closely related to the response rate and duration of the response of pleural effusion.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Nie et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: